Highlights Ocuphire Pharma, Inc.

Equities

OCUP

US67577R1023

Delayed Nasdaq Other stock markets 03:45:54 2024-05-02 pm EDT			5-day change	1st Jan Change
1.855 ^USD	+13.11%		+20.85%	-38.37%

Apr. 11	Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment	MT
Apr. 11	Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment	Apr. 11	MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	Apr. 11	CI
Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study	Apr. 11	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 08	CI
Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer	Feb. 14	CI
Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy	Feb. 05	CI
Ocuphire Pharma, Inc. Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity Under Dim Light Conditions	Jan. 04	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Ocuphire Pharma, Inc. Announces Successful End-Of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy	Nov. 02	CI
Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl?? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents	23-09-27	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Ocuphire Pharma, Inc. to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit	23-07-26	CI
Ocuphire Pharma, Inc. Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference	23-06-27	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-30	CI
Ocuphire Pharma, Inc. Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol Eye Drops for Reversal of Mydriasis	23-02-13	CI
Ocuphire Pharma, Inc. Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA	23-01-25	CI
Ocuphire Pharma Announces First Patient Enrolled in Vega-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia	23-01-09	CI
Ocuphire Pharma Files New Drug Application to FDA for Nyxol to Treat Pharmacologically-Induced Mydriasis	22-12-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ocuphire Pharma, Inc.

Equities

OCUP

US67577R1023

Highlights

Filters